Genor Biopharma Holdings Ltd. has provided a monthly update on its proposed merger involving the issuance of consideration shares under a specific mandate. This update follows a series of announcements related to the transaction, including the proposed merger, new listing application, and other related plans. The company highlighted that if certain conditions are not met, the merger agreement will not proceed. The announcement was made by Weng Chengyi, the Executive Director and Chief Financial Officer of Genor Biopharma Holdings Ltd., on June 13, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.